Brodtkorb TH, Knight C, Kamgar F, Teitsson S, Kurt M, Patel MY, Poretta T, Mamtani R, Palmer S. Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective1. J Med Econ. 2024 Apr 4;27(1):543-53. doi: 10.1080/13696998.2024.2329019
Teittson S, Brodtkorb T-H, Kurt M, Patel M, Poretta T, Knight C, Kamgar F, Palmer S. Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo. J Med Econ. 2024 Jan;27(1):473-81. doi: 10.1080/13696998.2024.2322394
Rothwell B, Kiff C, Ling C, Brodtkorb T-H. Cost effectiveness of nivolumab in patients with advanced, previously treated squamous and non-squamous non-small-cell lung cancer in England. Pharmacoecon Open. 2021 Jun;5(2):251-60. doi: 10.1007/s41669-020-00245-4
Anderson S, Carrico J, Brodtkorb T-H, Lalla D, Brufsky A. Budget impact of introducing neratinib for third-line treatment of human epidermal growth factor receptor 2 positive metastatic breast cancer in the United States. Poster presented at the 2021 Virtual AMCP; April 12, 2021. Previously presented at the 2020 Virtual San Antonio Breast Cancer (SABCS) Meeting.
Brodtkorb T-H, McDade C, Lalla D, Holmes FA. Cost-effectiveness of neratinib for the extended adjuvant treatment of adult patients with early-stage, HER2-overexpressed/amplified HR+ breast cancer who initiated neratinib within 1 year of completing trastuzumab in the U.S. Poster presented at the 2021 Virtual AMCP; April 2021. Previously presented at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS).
Popat S, Tanna N, Hartridge-Lambert S, Kiff C, Sowdani A, Rothwell B, Brodtkorb T-H, Ling C, Smittenaar R, Bomb M, Turnbull A. Nivolumab in second line non-small cell lung cancer – comparing real-world outcomes in England to CheckMate (CM) 017 and 057. Poster presented at the IASLC 2020 Virtual World Conference on Lung Cancer; January 28, 2021.
Anderson S, Carrico J, Brodtkorb T-H, Lalla D, Brufsky A. Budget impact of introducing neratinib for third-line treatment of HER2+ metastatic breast cancer in the United States. Poster presented at the 2020 Virtual San Antonio Breast Cancer (SABCS) Meeting; December 9, 2020.
Brodtkorb TH, McDade C, Lalla D, Holmes FA. Cost-effectiveness of neratinib for the extended adjuvant treatment of adult patients with early-stage, HR+, HER2-overexpressed/amplified breast cancer who initiated neratinib within 1 year of completing trastuzumab in the US. Poster presented at the 2020 Virtual San Antonio Breast Cancer (SABCS) Meeting; December 9, 2020.
Laramee P, Bell M, Irving A, Brodtkorb TH. The cost-effectiveness of the integration of nalmefene within the UK healthcare system treatment pathway for alcohol dependence. Alcohol Alcohol. 2016 May;51(3):283-90. doi: 10.1093/alcalc/agv140